AlphAIAlphAI — Financial news for AI agents
tradingview.com$AMPH

Amphastar Reports Q3 Revenue of $207.6 Million and Adjusted EPS of $1.14

Amphastar reported Q3 2026 revenue of $207.6M, up 8% YoY, with GAAP net income of $37.8M. Adjusted EPS was $1.14. Key products like BAQSIMI and Primatene MIST saw sales growth, while Lidocaine and Ipratropium bromide performed strongly. Teriparatide and API sales also contributed to growth. Manufacturing issues impacted some product sales and expenses.

Original reporting
tradingview.com
Published Nov 5, 2026, 9:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 9:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Amphastar Reports Q3 Revenue of $207.6 Million and Adjusted EPS of $1.14 — source image
Source · tradingview.com
Decision brief

The 30-second read

$AMPHBullishHigh
01

Why it matters

The earnings beat and revenue growth may trigger buying interest in the stock, while remediation costs could temper enthusiasm.

02

Market read

First‑report earnings release for a micro‑cap pharma, offering a fresh trading catalyst.

03

What to watch

Ongoing IMS remediation and facility expansion may pressure margins despite revenue growth.

Relevance 7/10Novelty 8/10Timing: after-market release today

Background

Amphastar filed an 8‑K with the SEC reporting its third‑quarter 2026 financial results.

Company-level read

Ticker impact

$AMPHBullishHigh confidence
Context

Amphastar Pharmaceuticals reported Q3 2026 revenue of $207.6M and adjusted EPS of $1.14, a material earnings release.

Expected impact

potential upside as market prices in the earnings beat

Evidence & confidence

Revenue grew 8% YoY and operating income more than doubled, indicating improved performance.

Market effects

Sector

Strengthens the generic pharma sector outlook with higher demand for inhalers and biosimilars.

Regional

Positive for US biotech investors tracking small-cap earnings.

Global

Limited to niche pharma investors; no broad market effect.

Counterpoint

What could challenge this read

Higher operating expenses from remediation could limit near‑term profit growth.

Key entities

  • company
    Amphastar Pharmaceuticals, Inc.

    US‑listed specialty pharmaceutical company (ticker AMPH).

Read at source← All news

StoryAmphastar posts Q3 2026 revenue of $207.6 million, GAAP profit of $37.8 million

Also covered by

5 outlets

Related articles

$AMPHHigh

Amphastar (AMPH) Q3 2026 Earnings Call Transcript

Amphastar (AMPH) reported Q3 2026 revenue of $207.6M, up 8% YoY, driven by BAQSIMI and Primatene MIST sales. Gross margin fell to 48% due to pricing pressures and IMS facility remediation costs. EPS rose to $1.14. The company increased its share buyback program by $50M and expects high single-digit Q4 growth. IMS backlog stands at $12.5M due to operational constraints. Insulin aspart launch is targeted for 2027, pending FDA approval.

fool.com
$AMPHHighAI 8/10

Amphastar Pharmaceuticals Inc (AMPH) Q3 2026 Earnings Call Highlights: Record Revenue

Amphastar Pharmaceuticals reported Q3 2026 revenue of $207.6M, up 8% YoY, with adjusted EPS of $1.14. CFO Bill Peters addressed pricing headwinds, IMS remediation costs, and growth drivers like Baximi and Primatene Mist. The company expects continued lidocaine demand but constrained capacity. Insulin biosimilar launches are planned for 2027, with margin normalization dependent on higher volumes. Q4 sales are expected to grow in the high single digits.

finance.yahoo.com
$AMPHMed

Amphastar Pharmaceuticals Q3 Earnings Call Highlights

Amphastar Pharmaceuticals reported Q3 gross margin decline to 48% from 51% YoY, citing lower pricing for BAQSIMI and increased manufacturing costs. The company expects higher remediation expenses in coming quarters. Amphastar aims to reduce a $12.5M backlog and sees continued lidocaine demand. It remains on track for potential 2027 launches of insulin aspart biosimilar and AMP-018, with other pipeline updates. Operating cash flow was $43.3M, and the board authorized $50M for share repurchases.

finance.yahoo.com
$AMPHHigh

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2026

Amphastar Pharmaceuticals, Inc. (AMPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 ​ Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2026 ​ - Net revenues of $207.6 million for the three months ended September 30, 2026 ​ - GAAP net income of $37.8 million, or $0.87 per share, for the third quarter ​ - Ad

SEC EDGAR 8-K